Over 10,000 results
S-1
CRGT
Cortigent, Inc.
20 Mar 23
IPO registration
5:26pm
vaccine product candidates.
Cortigent is increasingly dependent on sophisticated information technology systems, including systems from third parties … ) and Abraxane (cancer). At Cephalon (now Teva Pharmaceuticals) Mr. Dwyer was the head of regulatory affairs from 1993–1995 and from 1986–1993 he
S-1/A
AZTR
Azitra Inc
20 Mar 23
IPO registration (amended)
5:19pm
in the first half of 2024.
ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer … in certain cancer patients undergoing EGFRi targeted therapy by the end of 2023. Subject to FDA approval of our IND, we expect to commence our Phase 1b
8-K
EX-99.01
TNXP
Tonix Pharmaceuticals Holding Corp
20 Mar 23
Regulation FD Disclosure
5:07pm
Corp. Who We Are Tonix Pharmaceuticals is committed to improving population health by inventing and developing innovative therapies and vaccines … 9 Preclinical Gastric and colorectal cancers TNX - 1700 10 Phase 1, Targeted 2H 2023 Start Smallpox and mpox vaccine TNX - 801 11 Preclinical COVID
F-1/A
ZHYBF
Zhong Yuan Bio-Technology Holdings Ltd
20 Mar 23
Registration statement (foreign) (amended)
4:56pm
, BCG vaccine, etc.; and 15 drugs targeting synaptic plasticity and neuroprotection, including AGB101, AR1001, ATH-1017, etc. Pfizer, Roche, Eli Lilly … ) Medicine Technology, Inc. From February 2015 through October 2019, Dr. Dong was an associate professor at Sbarro Institute for Cancer Research
F-1/A
BSME
MED EIBY Holding Co., Ltd
20 Mar 23
Registration statement (foreign) (amended)
4:50pm
of 2022, COVID-19 vaccination programs have been greatly promoted around the globe, however several types of COVID-19 variants emerged in different parts … , and restrictions on business operations and large gatherings. From 2020 to the middle of 2022, COVID-19 vaccination programs have been greatly promoted around
424B3
eunwpp5 61x
20 Mar 23
Prospectus supplement
4:25pm
20-F
3nxt7 tcssww
20 Mar 23
Annual report (foreign)
11:26am
6-K
EX-99
8v89uji y0h7afu9ku
20 Mar 23
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
8:00am
8-K
EX-99.1
yq8821
17 Mar 23
Court Confirms Sorrento Therapeutics, Inc.’s $125 Million Arbitration Award Against NantPharma, LLC
6:37pm
POS AM
c3jhd
17 Mar 23
Prospectus update (post-effective amendment)
6:03pm
DEFC14A
zfs laq54o
17 Mar 23
Proxy in contested solicitation
5:26pm
424B3
6vva9t3wq
17 Mar 23
Prospectus supplement
4:56pm